{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "exchangeTimezoneName": "Asia/Taipei", "exchangeTimezoneShortName": "CST", "currency": "TWD", "market": "tw_market", "esgPopulated": false, "gmtOffSetMilliseconds": 28800000, "exchange": "TWO", "longName": "BRIM Biotechnology, Inc.", "shortName": "BRIM", "regularMarketPrice": 75.5, "regularMarketChangePercent": -1.0484967, "messageBoardId": "finmb_312052334", "marketState": "POSTPOST", "fiftyTwoWeekHighChangePercent": -0.17305589, "fiftyTwoWeekLow": 24.9, "fiftyTwoWeekHigh": 91.3, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "fiftyTwoWeekLowChange": 50.6, "fiftyTwoWeekLowChangePercent": 2.0321286, "fiftyTwoWeekRange": "24.9 - 91.3", "fiftyTwoWeekHighChange": -15.800003, "epsTrailingTwelveMonths": -3.85, "sharesOutstanding": 93254000, "fiftyDayAverage": 79.178, "fiftyDayAverageChange": -3.6780014, "fiftyDayAverageChangePercent": -0.046452314, "twoHundredDayAverage": 49.586765, "twoHundredDayAverageChange": 25.913235, "twoHundredDayAverageChangePercent": 0.52258366, "marketCap": 7040676864, "sourceInterval": 20, "exchangeDataDelayedBy": 20, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1656032400000, "priceHint": 2, "regularMarketChange": -0.80000305, "regularMarketTime": 1684133994, "regularMarketDayHigh": 76.9, "regularMarketDayRange": "74.9 - 76.9", "regularMarketDayLow": 74.9, "regularMarketVolume": 682547, "regularMarketPreviousClose": 76.3, "bid": 74.9, "ask": 75.5, "fullExchangeName": "Taipei Exchange", "regularMarketOpen": 76.2, "averageDailyVolume3Month": 1803074, "averageDailyVolume10Day": 716648, "symbol": "6885.TWO"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "No.1, Alley 30", "address2": "8F Lane 358, Ruiguang Rd. Neihu District", "city": "Taipei", "zip": "11492", "country": "Taiwan", "phone": "886 2 2659 8586", "fax": "886 2 2659 8779", "website": "https://www.brimbiotech.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis. The company was founded in 2013 and is based in Taipei, Taiwan.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Chyi Shyu  Wen Ph.D.", "title": "Chief Exec. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Haishan  Jang M.B.A., Ph.D.", "title": "Vice Chairman & Chief Global Strategist", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Yen  Amanda", "title": "VP of Fin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Kuo  Mei-Hui M.S.", "title": "Chief Operating Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Frank W.  Lee Ph.D.", "age": 71, "title": "Chief Strategic Officer", "yearBorn": 1951, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}